AbbVie Inc (ABBV)vsRobinhood Markets Inc (HOOD)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
HOOD
Robinhood Markets Inc
$77.03
+0.98%
FINANCIAL SERVICES · Cap: $68.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1262% more annual revenue ($62.82B vs $4.61B). HOOD leads profitability with a 41.1% profit margin vs 5.8%. HOOD trades at a lower P/E of 37.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HOOD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Intrinsic value data unavailable for HOOD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 38.5%
Large-cap with strong market position
Every $100 of equity generates 22 in profit
15.1% revenue growth
Generating 1.2B in free cash flow
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.7% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : HOOD
The strongest argument for HOOD centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 41.1% and operating margin at 38.5%. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : HOOD
The primary concerns for HOOD are P/E Ratio, EPS Growth, Debt/Equity. Debt-to-equity of 1.68 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while HOOD is a growth play — different risk/reward profiles.
HOOD carries more volatility with a beta of 2.29 — expect wider price swings.
HOOD is growing revenue faster at 15.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Robinhood Markets Inc
FINANCIAL SERVICES · CAPITAL MARKETS · USA
Robinhood Markets Inc (HOOD) is a pioneering fintech company that has transformed the retail investing landscape since its inception in 2013 by providing a commission-free trading platform accessible via an intuitive mobile app. The firm caters to a diverse user base, allowing access to a wide array of investment vehicles, including stocks, ETFs, options, and cryptocurrencies, while prioritizing financial literacy and inclusivity. By offering innovative features such as fractional shares and cash management solutions, Robinhood positions itself as a key player in the digital brokerage sector, appealing to a new generation of investors seeking efficient and transparent ways to engage with financial markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?